|
1
|
Bloom BR and Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 153:80–82. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
David JR: Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA. 56:72–77. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC and David JR: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA. 86:7522–7526. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A and Bucala R: Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry. 33:14144–14155. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K and Bucala R: Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med. 1:781–788. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun HW, Bernhagentt J, Bucalat R and Lolis E: Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA. 93:5191–5196. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T and Bucala R: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA. 93:7849–7854. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chesney J, Metz C, Bacher M, Peng T, Meinhardt A and Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 5:181–191. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang XR, Chun Hui CW, Chen YX, Wong BC, Fung PC, Metz C, Cho CH, Hui WM, Bucala R, Lam SK and Lan HY: Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology. 121:619–630. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Jüttner S, Brunner H and Bernhagen J: Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol. 280:85–102. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsunaga J, Sinha D, Pannell L, Santist C, Solano F, Wistow GJ and Hearing VJ: Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J Biol Chem. 274:3268–3271. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leech M, Metz C, Santos L, Peng T, Holdsworth SR, Bucala R and Morand EF: Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum. 41:910–917. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R and Morand EF: Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum. 42:1601–1608. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petrovsky N, Socha L, Silva D, Grossman AB, Metz C and Bucala R: Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol Cell Biol. 81:137–143. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA and Bucala R: MIF signal transduction initiated by binding to CD74. J Exp Med. 197:1467–1476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW and Yeh TM: Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg. 74:142–147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et al: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 13:587–596. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chuang YC, Su WH, Lei HY, Lin YS, Liu HS, Chang CP and Yeh TM: Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation. PLoS One. 7:e376132012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Chen Y, Wang C, Yang M, Wang Y, Bao L, Wang JE, Kim B, Chan KY, Xu W, et al: MIF is a 3′ flap nuclease that facilitates DNA replication and promotes tumor growth. Nat Commun. 12:29542021. View Article : Google Scholar
|
|
20
|
Michelet C: Evolutionary and functional analysis of macrophage migration inhibitory factors in eukaryotes. unpublished PhD thesis. COMUE Université Côte d'Azur; 2020, In French.
|
|
21
|
Jankauskas SS, Wong DWL, Bucala R, Djudjaj S and Boor P: Evolving complexity of MIF signaling. Cell Signal. 57:76–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sumaiya K, Langford D, Natarajaseenivasan K and Shanmughapriya S: Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther. 233:1080242022. View Article : Google Scholar
|
|
23
|
Merk M, Baugh J, Zierow S, Leng L, Pal U, Lee SJ, Ebert AD, Mizue Y, Trent JO, Mitchell R, et al: The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol. 182:6896–6906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng Q, McKeown SJ, Santos L, Santiago FS, Khachigian LM, Morand EF and Hickey MJ: Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J Immunol. 185:1238–1247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He XX, Yang J, Ding YW, Liu W, Shen QY and Xia HHX: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: Potential role of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu CT, Guo LL, Feng N, Zhang L, Zhou N, Ma LL, Shen L, Tong GH, Yan QW, Zhu SJ, et al: MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis. Oncotarget. 6:22410–22423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishihira J, Koyama Y and Mizue Y: Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine. 10:199–205. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pellowe AS, Sauler M, Hou Y, Merola J, Liu R, Calderon B, Lauridsen HM, Harris MR, Leng L and Zhang Y: Endothelial cell-secreted MIF reduces pericyte contractility and enhances neutrophil extravasation. FASEB J. 33:2171–2186. 2019. View Article : Google Scholar :
|
|
29
|
Farag AGA, Hammam MA, Habib MS, Elnaidany NF and Kamh ME: Macrophage migration inhibitory factor as an incriminating agent in vitiligo. An Bras Dermatol. 93:191–196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Waeber G, Calandra T, Roduit R, Haefliger JA, Bonny C, Thompson N, Thorens B, Temler E, Meinhardt A, Bacher M, et al: Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci USA. 94:4782–4787. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guda MR, Rashid MA, Asuthkar S, Jalasutram A, Caniglia JL, Tsung AJ and Velpula KK: Pleiotropic role of macrophage migration inhibitory factor in cancer. Am J Cancer Res. 9:2760–2773. 2019.
|
|
32
|
Kang I and Bucala R: The immunobiology of MIF: Function, genetics and prospects for precision medicine. Nat Rev Rheumatol. 15:427–437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nobre CCG, de Araújo JMG, de Medeiros Fernandes TAA, Cobucci RN, Lanza DCF, Andrade VS and Fernandes JV: Macrophage migration inhibitory factor (MIF): Biological activities and relation with cancer. Pathol Oncol Res. 23:235–244. 2017. View Article : Google Scholar
|
|
34
|
Osipyan A, Chen D and Dekker FJ: Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation. Drug Discov Today. 26:1728–1734. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou Y, Chen H, Liu L, Yu X, Sukhova GK, Yang M, Zhang L, Kyttaris VC, Tsokos GC, Stillman IE, et al: CD74 deficiency mitigates systemic lupus erythematosus-like autoimmunity and pathological findings in mice. J Immunol. 198:2568–2577. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Younan DNA, Agamia N, Elshafei A and Ebeid N: Serum level of macrophage migration inhibitory factor (MIF) in Egyptians with alopecia areata and its relation to the clinical severity of the disease. J Clin Lab Anal. 29:74–79. 2015. View Article : Google Scholar
|
|
37
|
Llamas-Covarrubias MA, Valle Y, Navarro-Hernández RE, Guzmán-Guzmán IP, Ramírez-Dueñas MG, Rangel-Villalobos H, Estrada-Chávez C and Muñoz-Valle JF: Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int. 32:2307–2311. 2012. View Article : Google Scholar
|
|
38
|
Mizue Y, Nishihira J, Miyazaki T, Fujiwara S, Chida M, Nakamura K, Kikuchi K and Mukai M: Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: Elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int J Mol Med. 5:397–403. 2000.PubMed/NCBI
|
|
39
|
Willeke P, Gaubitz M, Schotte H, Maaser C, Domschke W, Schlüter B and Becker H: Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome. Arthritis Res Ther. 9:R432007. View Article : Google Scholar
|
|
40
|
Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G and Wong J: Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 242:55–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fersching DMI, Nagel D, Siegele B, Salat C, Heinemann V, Holdenrieder S and Stoetzer OJ: Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. Anticancer Res. 32:2047–2058. 2012.PubMed/NCBI
|
|
42
|
Yamada G, Shijubo N, Takagi-Takahashi Y, Nishihira J, Mizue Y, Kikuchi K and Abe S: Elevated levels of serum macrophage migration inhibitory factor in patients with pulmonary tuberculosis. Clin Immunol. 104:123–127. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ganganna A, Subappa A and Bhandari P: Serum migration inhibitory factor levels in periodontal health and disease, its correlation with clinical parameters. Indian J Dent Res. 31:840–845. 2020. View Article : Google Scholar
|
|
44
|
Emonts M, Sweep FCGJ, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PW, Hazelzet JA and Calandra T: Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis. 44:1321–1328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Honda K, Nishihira J, Nitta K, Kobayashi H, Uchida K, Kawashima A, Yumura W and Nihei H: Serum levels of macrophage migration inhibitory factor in various types of glomerulonephritis. Nephron. 86:91–92. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee TJ, Chun JK, Yeon SI, Shin JS and Kim DS: Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease. Scand J Rheumatol. 36:222–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sugimoto H, Taniguchi M, Nakagawa A, Tanaka I, Suzuki M and Nishihira J: Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. Biochemistry. 38:3268–3279. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cooke G, Armstrong ME and Donnelly SC: Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. Biofactors. 35:165–168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fernández G, Arráiz De Fernández C, Valero N, Andrés Martínez J and López J: Adiponectin, hepatic steatosis and the prevention of child obesity. Enferm Inv. 5:17–24. 2020.In Spanish.
|
|
50
|
Farr L, Ghosh S and Moonah S: Role of MIF cytokine/CD74 receptor pathway in protecting against injury and promoting repair. Front Immunol. 11:12732020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B and Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 26:5046–5059. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matza D, Kerem A, Medvedovsky H, Lantner F and Shachar I: Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. Immunity. 17:549–560. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Schneppenheim J, Dressel R, Hüttl S, Lüllmann-Rauch R, Engelke M, Dittmann K, Wienands J, Eskelinen EL, Hermans-Borgmeyer I, Fluhrer R, et al: The intramembrane protease SPPL2a promotes B cell development and controls endosomal traffic by cleavage of the invariant chain. J Exp Med. 210:41–58. 2013. View Article : Google Scholar :
|
|
54
|
Bucala R and Shachar I: The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis. Mini Rev Med Chem. 14:1132–1138. 2014. View Article : Google Scholar
|
|
55
|
Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R and Bernhagen J: Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 18:688–703. 2006. View Article : Google Scholar
|
|
56
|
Gaber T, Schellmann S, Erekul KB, Fangradt M, Tykwinska K, Hahne M, Maschmeyer P, Wagegg M, Stahn C, Kolar P, et al: Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia. J Immunol. 186:764–774. 2011. View Article : Google Scholar
|
|
57
|
Mun SH, Oh D and Lee SK: Macrophage migration inhibitory factor down-regulates the RANKL-RANK signaling pathway by activating Lyn tyrosine kinase in mouse models. Arthritis Rheumatol. 66:2482–2493. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Guo Y, Pan W, Liu S, Shen Z, Xu Y and Hu L: ERK/MAPK signalling pathway and tumorigenesis (Review). Exp Ther Med. 19:1997–2007. 2020.PubMed/NCBI
|
|
59
|
Bucala R and Bernhagen J: MIF Family Cytokines in Innate Immunity and Homeostasis. Springer; Cham: 2018
|
|
60
|
Zhang S, Zhao J, Zhang Y, Zhang Y, Cai F, Wang L and Song W: Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer's disease. Alzheimers Res Ther. 11:542019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Heinrichs D, Berres ML, Coeuru M, Knauel M, Nellen A, Fischer P, Philippeit C, Bucala R, Trautwein C, Wasmuth HE and Bernhagen J: Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. FASEB J. 28:5136–5147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bencová S: Transcriptomic analysis of cutaneous inflammatory biomarkers in a mouse model of small fiber neuropathy. Univerzita Karlova, Farmaceutická fakulta v Hradci Králové; 2018
|
|
63
|
Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R and Young LH: Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature. 451:578–582. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shachar I: An essential MIF-CD74 signaling axis in kidney tubular regeneration, with prospects for precision medicine and pharmacological augmentation. Am J Physiol Renal Physiol. 313:F1084–F1086. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Stoppe C, Averdunk L, Goetzenich A, Soppert J, Marlier A, Kraemer S, Vieten J, Coburn M, Kowark A, Kim BS, et al: The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery. Sci Transl Med. 10:eaan48862018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sneath RJS and Mangham DC: The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 51:191–200. 1998. View Article : Google Scholar
|
|
67
|
Weng X, Maxwell-Warburton S, Hasib A, Ma L and Kang L: The membrane receptor CD44: Novel insights into metabolism. Trends Endocrinol Metab. 33:318–332. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Noe JT and Mitchell RA: MIF-dependent control of tumor immunity. Front Immunol. 11:6099482020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Calandra T and Roger T: Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol. 3:791–800. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Das R, Koo MS, Kim BH, Jacob ST, Subbian S, Yao J, Leng L, Levy R, Murchison C, Burman WJ, et al: Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 110:E2997–E3006. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ruiz-Rosado Jde D, Olguín JE, Juárez-Avelar I, Saavedra R, Terrazas LI, Robledo-Avila FH, Vazquez-Mendoza A, Fernández J, Satoskar AR, Partida-Sánchez S and Rodriguez-Sosa M: MIF promotes classical activation and conversion of inflammatory Ly6C(high) monocytes into TipDCs during murine toxoplasmosis. Mediators Inflamm. 2016:91017622016.PubMed/NCBI
|
|
72
|
Koga K, Kenessey A, Powell SR, Sison CP, Miller EJ and Ojamaa K: Macrophage migration inhibitory factor provides cardioprotection during ischemia/reperfusion by reducing oxidative stress. Antioxid Redox Signal. 14:1191–1202. 2011. View Article : Google Scholar
|
|
73
|
Luedike P, Hendgen-Cotta UB, Sobierajski J, Totzeck M, Reeh M, Dewor M, Lue H, Krisp C, Wolters D, Kelm M, et al: Cardioprotection through S-nitros(yl)ation of macrophage migration inhibitory factor. Circulation. 125:1880–1889. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rassaf T, Weber C and Bernhagen J: Macrophage migration inhibitory factor in myocardial ischaemia/reperfusion injury. Cardiovasc Res. 102:321–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Cherepkova OA, Lyutova EM, Eronina TB and Gurvits BY: Chaperone-like activity of macrophage migration inhibitory factor. Int J Biochem Cell Biol. 38:43–55. 2006. View Article : Google Scholar
|
|
76
|
Israelson A, Ditsworth D, Sun S, Song S, Liang J, Hruska-Plochan M, McAlonis-Downes M, Abu-Hamad S, Zoltsman G, Shani T, et al: Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron. 86:218–232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Leyton-Jaimes MF, Benaim C, Abu-Hamad S, Kahn J, Guetta A, Bucala R and Israelson A: Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS. Proc Natl Acad Sci USA. 113:10198–10203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Apte RS, Sinha D, Mayhew E, Wistow GJ and Niederkorn JY: Cutting edge: Role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 160:5693–5696. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M and Paus R: Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 128:1196–1206. 2008. View Article : Google Scholar
|
|
80
|
Matsuda A, Tagawa Y, Matsuda H and Nishihira A: Expression of macrophage migration inhibitory factor in corneal wound healing in rats. Invest Ophthalmol Vis Sci. 38:1555–1562. 1997.PubMed/NCBI
|
|
81
|
Nishio Y, Minami A, Kato H, Kaneda K and Nishihira J: Identification of macrophage migration inhibitory factor (MIF) in rat peripheral nerves: Its possible involvement in nerve regeneration. Biochim Biophys Acta. 1453:74–82. 1998. View Article : Google Scholar
|
|
82
|
Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ohkawara A and Shimizu H: High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol. 116:989–990. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Benigni F, Atsumi T, Calandra T, Metz C, Echtenacher B, Peng T and Bucala R: The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest. 106:1291–1300. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Stojanovic I, Saksida T and Stosic-Grujicic S: Beta cell function: The role of macrophage migration inhibitory factor. Immunol Res. 52:81–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bozza FA, Gomes RN, Japiassú AM, Soares M, Castro-Faria-Neto HC, Bozza PT and Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock. 22:309–313. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kim HR, Kim KW, Jung HG, Yoon KS, Oh HJ, Cho M La and Lee SH: Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res Ther. 13:E432011. View Article : Google Scholar
|
|
87
|
Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, Leal E, Juárez I, Whitacre C, Kithcart A, Pruitt J, Sielecki T, Satoskar AR and Rodriguez-Sosa M: Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 24:2583–2590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Donnelly SC, Hasleit C, Reid PT, Grant IS, Wallace WA, Metz CN, Bruce LJ and Bucala R: Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med. 3:320–323. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Benedek G, Meza-Romero R, Jordan K, Zhang Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, et al: MIF and D-DT are potential disease severity modifiers in male MS subjects. Proc Natl Acad Sci USA. 114:E8421–E8429. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tu Y, Guo R, Li J, Wang S, Leng L, Deng J, Bucala R and Lu L: MiRNA regulation of MIF in SLE and attenuation of murine lupus nephritis with miR-654. Front Immunol. 10:22292019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bezdek S, Leng L, Busch H, Mousavi S, Rades D, Dahlke M, Zillikens D, Bucala R and Sadik CD: Macrophage migration inhibitory factor (MIF) drives murine psoriasiform dermatitis. Front Immunol. 9:22622018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Rajabi F, Amoli MM, Robati RM, Almasi-nasrabadi M and Jabalameli N: Macrophage migration inhibitory factor polymorphism (rs755622) in alopecia areata: A possible role in disease prevention. Arch Dermatol Res. 311:589–594. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Chuang YC, Chen HR and Yeh TM: Pathogenic roles of macrophage migration inhibitory factor during dengue virus infection. Mediators Inflamm. 2015:5470942015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Mohla S: Tumor microenvironment. J Cell Biochem. 101:801–804. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wang Y and Dong X: MIF improves immune microenvironment of Lewis lung cancer brain metastases after radiotherapy via reducing M2 macrophages. J Clin Oncol. 40(16 Suppl): e210262022. View Article : Google Scholar
|
|
96
|
Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Balogh KN, Templeton DJ and Cross JV: Macrophage migration inhibitory factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One. 13:e01977022018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Faucheux L, Grandclaudon M, Perrot-Dockès M, Sirven P, Berger F, Hamy AS, Fourchotte V, Vincent-Salomon A, Mechta-Grigoriou F, Reyal F, et al: A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. Oncoimmunology. 8:e16241302019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Hanahan D: Hallmarks of cancer: New dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hashemi Goradel N, Najafi M, Salehi E, Farhood B and Mortezaee K: Cyclooxygenase-2 in cancer: A review. J Cell Physiol. 234:5683–5699. 2019. View Article : Google Scholar
|
|
103
|
Jäger B, Klatt D, Plappert L, Golpon H, Lienenklaus S, Barbosa PD, Schambach A and Prasse A: CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer. Cell Signal. 73:1096722020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cotzomi-Ortega I, Nieto-Yañez O, Juárez-Avelar I, Rojas-Sanchez G, Montes-Alvarado JB, Reyes-Leyva J, Aguilar-Alonso P, Rodriguez-Sosa M and Maycotte P: Autophagy inhibition in breast cancer cells induces ROS-mediated MIF expression and M1 macrophage polarization. Cell Signal. 86:1100752021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Cheng B, Wang Q, Song Y, Liu Y, Liu Y, Yang S, Li D, Zhang Y and Zhu C: MIF inhibitor, ISO-1, attenuates human pancreatic cancer cell proliferation, migration and invasion in vitro, and suppresses xenograft tumour growth in vivo. Sci Rep. 10:67412020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Vaupel P and Mayer A: Hypoxia in tumors: Pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv Exp Med Biol. 812:19–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Avalos-Navarro G, Muñoz-Valle JF, Daneri-Navarro A, Quintero-Ramos A, Franco-Topete RA, Morán-Mendoza AJ, Oceguera-Villanueva A, Bautista-Herrera LA, Topete-Camacho A and Del Toro-Arreola A: Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: Relationship with Th17 cytokine profile. Clin Exp Med. 19:385–391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Klemke L, De Oliveira T, Witt D, Winkler N, Bohnenberger H, Bucala R, Conradi LC and Schulz-Heddergott R: Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis. 12:1552021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Cotzomi-Ortega I, Rosas-Cruz A, Ramírez-Ramírez D, Reyes-Leyva J, Rodriguez-Sosa M, Aguilar-Alonso P and Maycotte P: Autophagy inhibition induces the secretion of macrophage migration inhibitory factor (MIF) with autocrine and paracrine effects on the promotion of malignancy in breast cancer. Biology (Basel). 9:202020.PubMed/NCBI
|
|
110
|
Rajendran G, Woolbright BL, Abbott E, Martin A, Dennis K and Taylor JA: Abstract 5150: MIF-2 in bladder cancer: Potential therapeutic target. Cancer Res. 80(16 Suppl): S51502020. View Article : Google Scholar
|
|
111
|
Richard V, Kindt N and Saussez S: Macrophage migration inhibitory factor involvement in breast cancer (Review). Int J Oncol. 47:1627–1633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Schabath MB and Cote ML: Cancer progress and priorities: Lung cancer. Cancer Epidemiol Biomarkers Prev. 28:1563–1579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Guo Y, Hou J, Luo Y and Wang D: Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human H460 lung cancer cells by caspase-dependent apoptosis. Cancer Cell Int. 13:282013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Gámez-Pozo A, Sánchez-Navarro I, Calvo E, Agulló-Ortuño MT, López-Vacas R, Díaz E, Camafeita E, Nistal M, Madero R, Espinosa E, et al: PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics. PLoS One. 7:e337522012. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang WM and Liu JC: Effect and molecular mechanism of mir-146a on proliferation of lung cancer cells by targeting and regulating MIF gene. Asian Pac J Trop Med. 9:806–811. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Huang WC, Kuo KT, Wang CH, Yeh CT and Wang Y: Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway. J Exp Clin Cancer Res. 38:1802019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mawhinney L, Armstrong ME, O'Reilly C, Bucala R, Leng L, Fingerle-Rowson G, Fayne D, Keane MP, Tynan A, Maher L, et al: Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. Mol Med. 20:729–735. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Liu L, Wang J, Wang Y, Chen L, Peng L, Bin Y, Ding P, Zhang R, Tong F and Dong X: Blocking the MIF-CD74 axis augments radiotherapy efficacy for brain metastasis in NSCLC via synergistically promoting microglia M1 polarization. J Exp Clin Cancer Res. 43:1282024. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Xiao Z, Song S, Chen D, van Merkerk R, van der Wouden PE, Cool RH, Quax WJ, Poelarends GJ, Melgert BN and Dekker FJ: Proteolysis targeting chimera (PROTAC) for macrophage migration inhibitory factor (MIF) has anti-proliferative activity in lung cancer cells. Angew Chem Int Ed Engl. 60:17514–17521. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gordon-Weeks AN, Lim SY, Yuzhalin AE, Jones K and Muschel R: Macrophage migration inhibitory factor: A key cytokine and therapeutic target in colon cancer. Cytokine Growth Factor Rev. 26:451–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Shin HN, Moon HH and Ku JL: Stromal cell-derived factor-1α and macrophage migration-inhibitory factor induce metastatic behavior in CXCR4-expressing colon cancer cells. Int J Mol Med. 30:1537–1543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Lechien JR, Nassri A, Kindt N, Brown DN, Journe F and Saussez S: Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review. Head Neck. 39:2573–2584. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Grieb G, Merk M, Bernhagen J and Bucala R: Macrophage migration inhibitory factor (MIF): A promising biomarker. Drug News Perspect. 23:257–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zarrin AA, Bao K, Lupardus P and Vucic D: Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov. 20:39–63. 2021. View Article : Google Scholar
|
|
125
|
Eaton WW, Rose NR, Kalaydjian A, Pedersen MG and Mortensen PB: Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 29:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Jacobson DL, Gange SJ, Rose NR and Graham NM: Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 84:223–243. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Wang L, Wang FS and Gershwin ME: Human autoimmune diseases: A comprehensive update. J Intern Med. 278:369–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Rosenblum MD, Remedios KA and Abbas AK: Mechanisms of human autoimmunity. J Clin Invest. 125:2228–2233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Günther S, Fagone P, Jalce G, Atanasov AG, Guignabert C and Nicoletti F: Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: From pathogenic factors to therapeutic targets. Drug Discov Today. 24:428–439. 2019. View Article : Google Scholar
|
|
130
|
Brown EM, Kenny DJ and Xavier RJ: Gut microbiota regulation of T cells during inflammation and autoimmunity. Annu Rev Immunol. 37:599–624. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Connelly KL, Kandane-Rathnayake R, Hoi A, Nikpour M and Morand EF: Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. Sci Rep. 6:299092016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Feng X, Chen W, Xiao L, Gu F, Huang J, Tsao BP and Sun L: Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus. Lupus. 26:62–72. 2017. View Article : Google Scholar
|
|
133
|
Fouda ME, El-shimi OS, Mahgoub MY, Abdelrahman SN and Abdelrahman AM: Evaluation of urinary and serum macrophage migration inhibition factor in a group of systemic lupus erythematosus Egyptian patients. Benha Med J. 39:164–178. 2022.
|
|
134
|
Vincent FB, Slavin L, Hoi AY, Kitching AR, Mackay F, Harris J, Kandane-Rathnayake R and Morand EF: Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. Lupus Sci Med. 5:e0002772018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Beltrán-Ramírez A, Muñoz-Valle JF, Gamez-Nava JI, Saldaña-Cruz AM, Gonzalez-Lopez L, Padilla-Ortega A, Arias-García FI, Sánchez-Zuno GA, Nava-Valdivia CA, Ponce-Guarneros JM, et al: Steroid resistance associated with high MIF and P-gp serum levels in SLE patients. Molecules. 27:67412022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Nim HT, Connelly K, Vincent FB, Petitjean F, Hoi A, Koelmeyer R, Boyd SE and Morand EF: Novel methods of incorporating time in longitudinal multivariate analysis reveals hidden associations with disease activity in systemic lupus erythematosus. Front Immunol. 10:16492019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
De la Cruz-Mosso U, García-Iglesias T, Bucala R, Estrada-García I, González-López L, Cerpa-Cruz S, Parra-Rojas I, Gámez-Nava JI, Pérez-Guerrero EE and Muñoz-Valle JF: MIF promotes a differential Th1/Th2/Th17 inflammatory response in human primary cell cultures: Predominance of Th17 cytokine profile in PBMC from healthy subjects and increase of IL-6 and TNF-α in PBMC from active SLE patients. Cell Immunol. 324:42–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wallace DJ, Wegener WA, Horne H and Goldenberg DM: CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE). Lupus Sci Med. 3:A37–A38. 2016.
|
|
139
|
Bautista-Herrera LA, De la Cruz-Mosso U, Román-Fernández IV, Parra-Rojas I, Soñanez-Organis JG, Hernández-Bello J, Morales-Zambrano RA, Villanueva-Quintero GD and Muñoz-Valle JF: A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile. Int J Immunopathol Pharmacol. 34:20587384209071862020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Morales-Zambrano R, Bautista-Herrera LA, De La Cruz-Mosso U, Villanueva-Quintero GD, Padilla-Gutiérrez JR, Valle Y, Parra-Rojas I, Rangel-Villalobos H, Gutiérrez-Ureña SR and Muñoz-Valle JF: Macrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNFα in psoriatic arthritis. Int J Clin Exp Med. 7:2605–2614. 2014.
|
|
141
|
Schneeberger EE, Citera G, Rodríguez Gil G, Granel A, Arturi A, Rosemffet GM, Maldonado Cocco JA, Berman A, Spindler A and Morales VH: Clinical and immunogenetic characterization in psoriatic arthritis patients. Clin Rheumatol. 34:1413–1418. 2015. View Article : Google Scholar
|
|
142
|
Barnas JL and Ritchlin CT: Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin North Am. 41:643–663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Veale DJ and Fearon U: The pathogenesis of psoriatic arthritis. Lancet. 391:2273–2284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Steinhoff M, Meinhardt A, Steinhoff A, Gemsa D, Bucala R and Bacher M: Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol. 141:1061–1066. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Chhabra S, Banerjee N, Narang T, Sood S, Bishnoi A, Goel S, Bansal F, Singh S, Priyanka K, Minz RW and Dogra S: Single-nucleotide polymorphism and haplotype analysis of macrophage migration inhibitory factor gene and its correlation with serum macrophage migration inhibitory factor levels in North Indian psoriatic patients with moderate disease severity: A cross-sectional study. Indian J Dermatol Venereol Leprol. 89:247–253. 2023. View Article : Google Scholar
|
|
146
|
Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW and Griffiths CEM: Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol. 123:484–487. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Dobson R and Giovannoni G: Multiple sclerosis-a review. Eur J Neurol. 26:27–40. 2019. View Article : Google Scholar
|
|
148
|
Cavalli E, Mazzon E, Basile MS, Mangano K, Di Marco R, Bramanti P, Nicoletti F, Fagone P and Petralia MC: Upregulated Expression of Macrophage Migration Inhibitory Factor, Its Analogue D-Dopachrome Tautomerase, and the CD44 Receptor in Peripheral CD4 T cells from clinically isolated syndrome patients with rapid conversion to clinical defined multiple sclerosis. Medicina (Kaunas). 55:6672019. View Article : Google Scholar
|
|
149
|
Wanleenuwat P and Iwanowski P: Role of B cells and antibodies in multiple sclerosis. Mult Scler Relat Disord. 36:1014162019. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Guan D, Li Y, Cui Y, Zhao H, Dong N, Wang K, Ren D, Song T, Wang X, Jin S, et al: 5-HMF attenuates inflammation and demyelination in experimental autoimmune encephalomyelitis mice by inhibiting the MIF-CD74 interaction. Acta Biochim Biophys Sin (Shanghai). 55:1222–1233. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Hjæresen S, Sejbaek T, Axelsson M, Mortensen SK, Vinsløv-Jensen H, Pihl-Jensen G, Novakova L, Pedersen CB, Halle B, Poulsen FR, et al: MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. J Neurol Sci. 439:1203202022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Rijvers L, Melief MJ, van der Vuurst de Vries RM, Stéphant M, van Langelaar J, Wierenga-Wolf AF, Hogervorst JM, Geurts-Moespot AJ, Sweep FCGJ, Hintzen RQ and van Luijn MM: The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis. Eur J Immunol. 48:1861–1871. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Castañeda-Moreno VA, De la Cruz-Mosso U, Torres-Carrillo N, Macías-Islas MA, Padilla-De la Torre O, Mireles-Ramírez MA, González-Pérez O, Ruiz-Sandoval JL, Huerta M, Trujillo X, et al: MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population. J Neuroimmunol. 320:117–124. 2018. View Article : Google Scholar
|
|
154
|
Vandenbark AA, Meza-Romero R, Benedek G and Offner H: A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury. J Neuroinflammation. 16:142019. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, Sherry B, Coleman T, Forsthuber T and Al-Abed Y: Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem. 291:26502–26514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, et al: Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 379:846–855. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Pawlitzki M, Sweeney-Reed CM, Meuth SG, Reinhold D and Neumann J: CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis. PLoS One. 13:e02077262018. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Eldesouky F, Ibrahim AM and Sharaf SM: Macrophage migration inhibitory factor in alopecia areata and vitiligo: A case-controlled serological study. J Clin Aesthet Dermatol. 13:24–27. 2020.
|
|
159
|
Sandoval DA and Plaza NE: Collapse of the immunoprivilege and emotional stress in alopecia areata. Rev Argent Dermatol. 101:41–50. 2020.
|
|
160
|
Oh HA, Kwak J, Kim BJ, Jin HJ, Park WS, Choi SJ, Oh W and Um S: Migration inhibitory factor in conditioned medium from human umbilical cord blood-derived mesenchymal stromal cells stimulates hair growth. Cells. 9:13442020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Garcia-Orozco A, Martinez-Magaña IA, Riera-Leal A, Muñoz-Valle JF, Martinez-Guzman MA, Quiñones-Venegas R, Sánchez-Zuno GA and Fafutis-Morris M: Macrophage inhibitory factor (MIF) gene polymorphisms are associated with disease susceptibility and with circulating MIF levels in active non-segmental vitiligo in patients from western Mexico. Mol Genet Genomic Med. 8:e14162020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ibrahim HM, Abd El-Aziz Nada EED, Abdel-Hamid Ali S, Hegazy EM and Hassan MH: Macrophage migration inhibitory factor in vitiligo: Pathogenesis and potential therapeutic aspects. Asian J Biochem Genet Mol Biol. 8:8–24. 2021. View Article : Google Scholar
|
|
163
|
Solimani F, Meier K and Ghoreschi K: Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 10:28472019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Chakraborty A, Thulasamma S, Kumar GS, Pallapolu P, Lahari K, Rafeeqi T, Husain G, Jabeen F, Javed G, Waheed MA and Kazmi MH: Expression levels of MIF, NLRP1 and FOXP3 genes along with biomarker levels in patients with active form of non-segmental generalized vitiligo: A study in South Indian population. Songklanakarin J Sci Technol. 44:353–360. 2022.
|
|
165
|
Wang D, Min S, Lin X and Jiang G: Association among MIF, IFIH1, and IL6 gene polymorphisms and non-segmental vitiligo in a chinese han population. Clin Cosmet Investig Dermatol. 15:1597–1609. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
ElGhareeb MI, El Mokadem S, El Sayed B and Khalifa N: Soluble CD27 and MIF as possible serum biomarkers of vitiligo activity in Egyptian patients in Sharkia governorate. Dermatol Reports. 11:82652019.
|
|
167
|
Bae SC and Lee YH: Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between MIF gene polymorphisms and disease susceptibility: A meta-analysis. Postgrad Med J. 94:109–115. 2018. View Article : Google Scholar
|
|
168
|
Han Y, Wang J, Li S, Li Y, Zhang Y, Zhang R, Zhang Y, Fan H, Shi H, Pan J, et al: Isopsoralen ameliorates rheumatoid arthritis by targeting MIF. Arthritis Res Ther. 23:2432021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Taghadosi M, Adib M, Jamshidi A, Mahmoudi M and Farhadi E: The p53 status in rheumatoid arthritis with focus on fibroblast-like synoviocytes. Immunol Res. 69:225–238. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Zhang Z, Zhang R, Li L, Zhu L, Gao S, Lu Q, Gu Y, Zhang Y, Yang H, Hou T, et al: Macrophage migration inhibitory factor (MIF) inhibitor, Z-590 suppresses cartilage destruction in adjuvant-induced arthritis via inhibition of macrophage inflammatory activation. Immunopharmacol Immunotoxicol. 40:149–157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Södergren A, Kar p K, Bengtsson C, Möller B, Rantapää-Dahlqvist S and Wållberg-Jonsson S: Biomarkers associated with cardiovascular disease in patients with early rheumatoid arthritis. PLoS One. 14:e02205312019. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Santoscoy-Ascencio G, Baños-Hernández CJ, Navarro-Zarza JE, Hernández-Bello J, Bucala R, López-Quintero A, Valdés-Alvarado E, Parra-Rojas I, Illades-Aguiar B and Muñoz-Valle JF: Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico. Mol Genet Genomic Med. 8:e10372020. View Article : Google Scholar :
|
|
173
|
Hernández-Palma LA, García-Arellano S, Bucala R, Llamas-Covarrubias MA, De la Cruz-Mosso U, Oregon-Romero E, Cerpa-Cruz S, Parra-Rojas I, Plascencia-Hernández A and Muñoz-Valle JF: Functional MIF promoter haplotypes modulate Th17-related cytokine expression in peripheral blood mononuclear cells from control subjects and rheumatoid arthritis patients. Cytokine. 115:89–96. 2019. View Article : Google Scholar
|
|
174
|
García-Arellano S, Hernández-Palma LA, Cerpa-Cruz S, Sánchez-Zuno GA, Herrera-Godina MG and Muñoz-Valle JF: The novel role of MIF in the secretion of IL-25, IL-31, and IL-33 from PBMC of patients with rheumatoid arthritis. Molecules. 26:49682021. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Sogkas G, Klose K, Baerlecken N, Schweikhard E, Matthias T, Kniesch K, Schmidt RE and Witte T: CD74 is a T cell antigen in spondyloarthritis. Clin Exp Rheumatol. 38:195–202. 2020. View Article : Google Scholar
|
|
176
|
Sánchez-Zuno GA, Bucala R, Hernández-Bello J, Román-Fernández IV, García-Chagollán M, Nicoletti F, Matuz-Flores MG, García-Arellano S, Esparza-Michel JA, Cerpa-Cruz S, et al: Canonical (CD74/CD44) and non-canonical (CXCR2, 4 and 7) MIF receptors are differentially expressed in rheumatoid arthritis patients evaluated by DAS28-ESR. J Clin Med. 11:1202021. View Article : Google Scholar
|
|
177
|
Valdez CN, Sánchez-Zuno GA, Bucala R and Tran TT: Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT): Pathways to tumorigenesis and therapeutic opportunities. Int J Mol Sci. 25:48492024. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
de Azevedo RA, Shoshan E, Whang S, Markel G, Jaiswal AR, Liu A, Curran MA, Travassos LR and Bar-Eli M: MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 9:18469152020. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Mora Barthelmess R, Stijlemans B and Van Ginderachter JA: Hallmarks of cancer affected by the MIF cytokine family. Cancers (Basel). 15:3952023. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Valdez CN, Athziri Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni RP, Kang I, Bucala R and Tran T: Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget. 15:507–520. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Sánchez-Zuno GA, Valdez CN, Osmani L, Kang I, Bucala R and Tran T: 571 Dual inhibition of MIF and DDT enhances the efficacy of anti-PD-1 therapy in murine melanoma. J Immunother Cancer. 12:A6512024.
|
|
182
|
Bloom J, Pantouris G, He M, Aljabari B, Mishra L, Manjula R, Parkins A, Lolis EJ and Al-Abed Y: Iguratimod, an allosteric inhibitor of macrophage migration inhibitory factor (MIF), prevents mortality and oxidative stress in a murine model of acetaminophen overdose. Mol Med. 30:432024. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Jiang H, Gao H, Wang Q, Wang M and Wu B: Molecular mechanisms and clinical application of iguratimod: A review. Biomed Pharmacother. 122:1097042020. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Long Z, Zeng L, He Q, Yang K, Xiang W, Ren X, Deng Y and Chen H: Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases. Front Immunol. 14:11506612023. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Efferth T and Oesch F: The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases. Med Res Rev. 41:3023–3061. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Ruwizhi N, Maseko RB and Aderibigbe BA: Recent advances in the therapeutic efficacy of artesunate. Pharmaceutics. 14:5042022. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Guo S, Zhao Y, Yuan Y, Liao Y, Jiang X, Wang L, Lu W and Shi J: Progress in the development of macrophage migration inhibitory factor small-molecule inhibitors. Eur J Med Chem. 286:1172802025. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Chen D, Zhao C, Zhang J, Knol CWJ, Osipyan A, Majerníková N, Chen T, Xiao Z, Adriana J and Griffith AJ: Small molecule MIF modulation enhances ferroptosis by impairing DNA repair mechanisms. Adv Sci (Weinh). 11:e24039632024. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Li J, Leng L, Pantouris G, Manjula R, Piecychna M, Abriola L, Hu B, Lolis E, Armstrong ME, Donnelly SC and Bucala R: A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus. J Biol Chem. 300:1074432024. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Sanchez-Zuno GA, Caulfield J, Leng L, Zhang L, Jilaveanu L, Kluger H, Bucala R and Tran T: 830 Inhibition of macrophage migration inhibitory factor (MIF) to overcome immune checkpoint resistance in melanoma. J Immunother Cancer. 11(Suppl 1): S9292023.
|
